Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.80M | $311K | — | $6.83M | $32.2M | $18.4M | $9.43M | $0.00 | $0.00 | $7.50M |
| Revenue growth | — | -82.8% | — | — | 371.0% | -42.7% | -48.8% | -100.0% | — | — |
| Operating income | -$24.8M | -$32.6M | -$38.0M | -$42.8M | -$31.3M | -$79.0M | -$129M | -$214M | -$279M | -$373M |
| Operating margin | -1376.4% | -10474.3% | — | -627.0% | -97.3% | -428.4% | -1368.9% | — | — | -4974.3% |
| Net income | -$23.0M | -$30.7M | -$34.5M | -$41.6M | -$28.8M | -$78.9M | -$125M | -$182M | -$234M | -$346M |
| Net margin | -1275.5% | -9872.7% | — | -609.1% | -89.7% | -427.8% | -1328.9% | — | — | -4612.1% |
| EPS (diluted) | -$1.48 | -$1.72 | -$1.63 | -$1.54 | -$0.81 | -$1.77 | -$2.06 | -$2.73 | -$3.01 | -$4.36 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.6M | -$28.7M | -$34.7M | -$4.71M | -$48.1M | -$69.5M | -$101M | -$151M | -$181M | -$279M |
| Capital expenditures | $279K | $315K | $507K | $1.24M | $2.64M | $2.05M | $2.89M | $5.62M | $3.08M | $799K |
| Free cash flow | -$19.8M | -$29.0M | -$35.2M | -$5.95M | -$50.8M | -$71.6M | -$104M | -$157M | -$184M | -$280M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17.1M | $20.5M | $67.8M | $24.8M | $45.0M | $176M | $57.2M | $149M | $143M | $199M |
| Total assets | $67.5M | $46.1M | $122M | $148M | $189M | $572M | $754M | $965M | $798M | $633M |
| Total liabilities | $3.59M | $10.2M | $19.1M | $55.7M | $17.8M | $22.0M | $32.6M | $36.9M | $43.2M | $51.4M |
| Long-term debt | — | $6.10M | $15.0M | $10.9M | — | — | — | — | — | — |
| Shareholders' equity | $63.9M | $35.9M | $103M | $92.0M | $171M | $550M | $721M | $928M | $755M | $582M |
| Retained earnings | -$143M | -$173M | -$208M | -$250M | -$278M | -$357M | -$483M | -$665M | -$899M | -$1.25B |
| Shares (wtd avg diluted) | 15.5M | 18.0M | 19.4M | 28.1M | 34.5M | 43.6M | 60.5M | 66.9M | 77.9M | 79.3M |
Every figure is extracted from Xenon Pharmaceuticals Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.